Dedifferentiated liposarcoma is a fast-growing and more aggressive type of soft tissue sarcoma that originates as a well-differentiated sarcoma and has a typical diagnosis age of 40 to 60 years. DDLPS ...

From 1984 to 2000, 124 patients with a retroperitoneal sarcoma were referred to our center for the treatment of the primary tumor or the first local recurrence. These sarcomas were 58 liposarcomas (21 ...

Randomized, placebo-controlled, double blind, phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors. This is an ASCO Meeting Abstract ...

Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma. This is an ASCO Meeting Abstract from the 2021 ASCO Annual Meeting I. This abstract does not include a full ...

However, the specific genetic changes that distinguish between well-differentiated liposarcoma and dedifferentiated liposarcoma are poorly understood. As a group, dedifferentiated liposarcomas show ...

Please provide your email address to receive an email when new articles are posted on . Abemaciclib extended PFS vs. placebo for patients with advanced dedifferentiated liposarcoma. SARC041 is the ...

Please provide your email address to receive an email when new articles are posted on . Milademetan failed to significantly extend PFS among patients with dedifferentiated liposarcoma, according to ...

NEWARK, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics with its lead product candidate, ...

CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to ...